Stock ALGS ALIGOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Aligos Therapeutics, Inc.

Equities

ALGS

US01626L1052

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
0.8101 USD -4.24% Intraday chart for Aligos Therapeutics, Inc. -0.97% +22.00%
04-03 Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects CI
03-27 Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies CI

Business Summary

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.

Number of employees: 66

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Therapeutics
100.0 %
14 100.0 % 16 100.0 % +11.66%

Managers

Managers TitleAgeSince
Lucinda Quan FOU
 Founder 51 04/02/18
Lawrence Blatt CEO
 Chief Executive Officer 62 04/02/18
Lesley Calhoun DFI
 Director of Finance/CFO 58 31/05/20
Matthew McClure CTO
 Chief Tech/Sci/R&D Officer 53 31/07/19
Julian Symons CTO
 Chief Tech/Sci/R&D Officer 63 30/04/18
Jordyn Tarazi IRC
 Investor Relations Contact - 02-12
Kristina Engeseth HRO
 Human Resources Officer - -
Sushmita M. Chanda PRN
 Corporate Officer/Principal 58 31/07/18

Members of the board

Members of the board TitleAgeSince
Lawrence Blatt CEO
 Chief Executive Officer 62 04/02/18
Carole Nüchterlein BRD
 Director/Board Member 63 31/07/18
K. Hirth BRD
 Director/Board Member 72 31/07/18
Jim Scopa BRD
 Director/Board Member 65 26/04/21
Jack Nielsen BRD
 Director/Board Member 60 31/07/18
Bridget Martell BRD
 Director/Board Member 58 15/11/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 3,092,338 0 0 78.90 %
Stock B 1 72,576,183 59,705,184 ( 82.27 %) 0

Shareholders

NameEquities%Valuation
ROCHE HOLDING AG
15.19 %
11,025,941 15.19 % 11 M $
Armistice Capital LLC
9.416 %
6,833,875 9.416 % 7 M $
EcoR1 Capital, LLC
8.804 %
6,389,468 8.804 % 6 M $
Deep Track Capital LP
8.409 %
6,102,770 8.409 % 6 M $
Vivo Capital LLC
4.887 %
3,547,030 4.887 % 3 M $
Alyeska Investment Group LP
3.971 %
2,882,216 3.971 % 3 M $
Altitude Crest Partners, Inc.
3.920 %
2,844,681 3.920 % 3 M $
Versant Venture Management LLC
3.197 %
2,320,381 3.197 % 2 M $
Tang Capital Management LLC
3.017 %
2,189,847 3.017 % 2 M $
Lawrence Blatt
2.922 %
2,120,633 2.922 % 2 M $

Company contact information

Aligos Therapeutics, Inc.

1 Corporate Drive 2nd floor

94080, South San Francisco

+800 466 6059

http://www.aligos.com
address Aligos Therapeutics, Inc.(ALGS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.846 USD
Average target price
4 USD
Spread / Average Target
+372.81%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALIGOS THERAPEUTICS, INC. Stock Aligos Therapeutics, Inc.
+22.00% 66.08M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 48.09B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 40.62B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.43B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.36B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 24.89B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.01B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 11.88B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.8B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALGS Stock
  4. Company Aligos Therapeutics, Inc.